PatientsVille.com Logo

CEREBROVASCULAR ACCIDENT and Ranitidine

PatientsVille

CEREBROVASCULAR ACCIDENT Symptoms and Causes

A stroke is a medical emergency. There are two types - ischemic and hemorrhagic. Ischemic stroke is the most common type. It is usually caused by a blood clot that blocks or plugs a blood vessel in the brain. This keeps blood from flowing to the brain. Within minutes, brain cells begin to die. Another cause is stenosis, or narrowing of the artery. This can happen because of atherosclerosis, a disease in which plaque builds up inside your arteries. Transient ischemic attacks (TIAs) occur when the blood supply to the brain is interrupted briefly. Having a TIA can mean you are at risk for having a more serious stroke.

Symptoms of stroke are

  • Sudden numbness or weakness of the face, arm or leg (especially on one side of the body)
  • Sudden confusion, trouble speaking or understanding speech
  • Sudden trouble seeing in one or both eyes
  • Sudden trouble walking, dizziness, loss of balance or coordination
  • Sudden severe headache with no known cause

It is important to treat strokes as quickly as possible. Blood thinners may be used to stop a stroke while it is happening by quickly dissolving the blood clot. Post-stroke rehabilitation can help people overcome disabilities caused by stroke damage.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for CEREBROVASCULAR ACCIDENT

CEREBROVASCULAR ACCIDENT treatment research studies

Ranitidine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ranitidine Side Effects

Dyspnoea (125)
Anaphylactic Reaction (77)
Hypotension (71)
Diarrhoea (67)
Nausea (65)
Vomiting (62)
Urticaria (59)
Abdominal Pain (46)
Dizziness (43)
Malaise (43)
Cardiac Arrest (40)
Pain (39)
Loss Of Consciousness (37)
Fatigue (36)
Angioedema (35)
Confusional State (34)
Renal Failure Acute (33)
Pruritus (32)
Headache (32)
Chest Pain (31)
Abdominal Pain Upper (29)
Overdose (27)
Bradycardia (27)
Rash (27)
Pyrexia (25)
Hypersensitivity (24)
Dyspepsia (23)
Circulatory Collapse (23)
Chest Discomfort (22)
Erythema (21)
Thrombocytopenia (21)
Gastrooesophageal Reflux Disease (21)
Product Quality Issue (21)
Weight Decreased (20)
Burning Sensation (20)
Alanine Aminotransferase Increased (20)
Paraesthesia (20)
Cholelithiasis (20)
Dysgeusia (19)
Neutropenia (19)
Cough (19)
Flushing (19)
Hypertension (19)
Tubulointerstitial Nephritis (18)
Condition Aggravated (17)
Feeling Abnormal (17)
Depression (17)
Vision Blurred (17)
Agitation (16)
Heart Rate Increased (16)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Emotional Anxciety then chest pain, jaw pain on left side and headaches, I am not taking it no more. there has to be something else less tramatising to my system. It was bad enugh that i was at work when the emotional anxiety hit. not cool at all.

<strong>gracia por la informacion</strong>

*DONT_KNOW* guess that's an honest answer

Has there been any evidence linking ranitidine to lower back or hip problems?

Is Histac 150 a pain reliever for slip disc backache?

Will Marinol further damage, an already diseased liver

<span style='color: #808080;'>i took dihydracodine and got great painless hours after a serious motorcycle accident , i wont go into details and bore you ,<span style='text-decoration: underline;'>i am now on methadone for life,<strong

1 am a 26 year old male with a 14 year historical user of various Narcotic Drugs. Currently on Hydrocodon (10mg - 325 APAP) due to extensive surgeries for an auto accident and second lessor motorcycle accident. Both caused by DUIs. High anxiety

48YO male, obese, diabetic, hypertensive, mild anxiety and depression. R BKA, R Acetabula fracture 13 years ago from motorcycle accident. Swollen gall bladder removed during hospitalization. Current meds include Metformin (withheld pre- and post- ct)

55 year old female. Healthy but was in a Pedestrian versus auto accident. She was told to take Tizanidine for sore muscles from the accidnet. 2mg tabs about 2 x per day. I experienced horrible fatigue and exhau

Are u still on epanutin if i may ask, i had a head injury after accident and have been taking it for the last 2 years did u stop taking it??

Came across this site by accident so if anyone has any recommendations re the pain please email me <a href='mailto:lynn.rider@sky.com'>lynn.rider@sky.com</a> many thanks

Coma causing motor cycle accident. brain damage. family difficulties not being able to work causing financial problems

Dear Doctors, My brother is 22 years old. He had an accident and had insomnia, depression, anger, feeling guilt of smashing the car and had some childhood flashbacks for about a week and was hospitalized. The time he was admitted to hospit

Debilitating dizziness, while driving at night, the traffic lights and street lights started spinning left to right around my head, almost causing an accident as I tried to pull off the road and stop I was in the emergency ward for 3 days w

Had an MRI last Monday, Thursday drs. office called and said I had damaged my graft. I dont understand because I had a car accident in August 9 weeks after my surgery and they did an mri and x-ray and said everything was fine. I have lost alot of mob

CEREBROVASCULAR ACCIDENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Comparison of Pantoprazole and Ranitidine in Dyspepsia
Condition: Dyspepsia
Interventions: Drug: Pantoprazole;   Drug: Ranitidine
Outcome Measures: Visual analogue scale score;   Need for additional drug
2 Recruiting TPI 287 in Breast Cancer Metastatic to the Brain
Condition: Breast Cancer
Interventions: Drug: TPI 287;   Drug: Dexamethasone;   Drug: Benadryl;   Drug: Ranitidine
Outcome Measure: Overall Response Rate
3 Recruiting Treatment of Orthostatic Hypotension in Autonomic Failure
Conditions: Autonomic Failure;   Orthostatic Hypotension
Interventions: Drug: Atomoxetine;   Drug: Acarbose;   Drug: Pyridostigmine Bromide;   Drug: Yohimbine;   Drug: Midodrine HCl;   Drug: placebo;   Drug: Modafinil;   Drug: Octreotide;   Other: water intake;   Drug: Diphenhydramine Hydrochloride;   Drug: Ranitidine HCL;   Drug: Tranylcypromine;   Drug: Ergotamine/ Caffeine;   Drug: Celecoxib;   Drug: Pseudoephedrine;   Drug: Methylphenidate;   Drug: Indomethacin;   Drug: Ibuprofen;   Drug: Oxymetazoline 0.05% nasal solution;   Dietary Supplement: Bovril;   Drug: Acetazolamide;   Drug: Rivastigmine tartrate;   Drug: Carbidopa/levodopa;   Device: Inflatable abdominal binder;   Device: inflatable abdominal binder (sham)
Outcome Measures: Increase in seated systolic blood pressure 1-hr post drug compared to baseline.;   Increase in standing time 1-hr post drug compared to baseline
4 Not yet recruiting The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux
Conditions: Eustachian Tube Dysfunction;   Laryngopharyngeal Reflux
Interventions: Drug: Omeprazole;   Drug: Ranitidine;   Drug: Pantoprazole;   Procedure: 24-Hour Diagnostic pH-Probe Test;   Procedure: Laryngoscopy
Outcome Measure: Evidence of laryngopharyngeal reflux in patients complaining of ear fullness/pressure/pain
5 Recruiting Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
Conditions: Pharmacokinetics;   Voriconazole
Intervention: Drug: Midazolam/Ranitidine/Esomeprazole
Outcome Measures: Voriconazole steady-state pharmacokinetics;   Voriconazole drug metabolizing enzyme activity
6 Recruiting Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
Conditions: Parapneumonic Pleural Effusion;   Empyema
Interventions: Drug: Dexamethasone;   Drug: Placebo
Outcome Measures: time to resolution;   number of children with complications.;   Number of children with complications attributable to corticoids
7 Unknown  Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Condition: Poisoning
Interventions: Drug: Chlorphenamine and Ranitidine;   Drug: Paracetamol
Outcome Measures: Attenuation of NAC induced vasodilatation by histamine antagonists (H1 and H2 antagonists) and/or paracetamol;   Inhibition of the inflammatory cascade contributes to a paracetamol mediated protective role against NAC adverse reactions.
8 Unknown  Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Condition: Dyspepsia
Intervention: Procedure: gastroscopic examination
Outcome Measures: Incidence of H. pylori Clarithromycin resistance gene;   Characteristic of H. pylori clarithromycin resistant gene mutation
9 Unknown  Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study
Condition: Helicobacter Pylori Infection
Interventions: Drug: Group A: NCA 600 mg+antibiotics;   Drug: Group B: antibiotic treatment (control)
Outcome Measure: To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure
10 Recruiting Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme (GBM) WHO Grade IV
Intervention: Drug: Cabazitaxel
Outcome Measures: Response including SD, PR or CR determined by MRI (modified RANO criteria);   Overall and progression-free survival;   Safety and tolerability;   Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction);   Quality of life and neurocognitive functioning
11 Recruiting Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: carboplatin
Outcome Measures: To determine if patients have lower rates of hypersensitivity reactions compared to those treated with standard infusion carboplatin.;   Determine the rate of successful planned treatment completion of carboplatin in each group;   Perform a cost-identification analysis of extended infusion carboplatin to estimate the cost per hypersensitivity reaction prevented.;   Perform exploratory analyses to correlate hypersensitivity rate to history of atopy, prior drug allergies, number of lifetime platinum cycles, duration since last platinum, and concomitant chemotherapy agent.
12 Not yet recruiting Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Condition: Breast Neoplasms
Interventions: Drug: Vintafolide 2.5 mg;   Drug: Paclitaxel 80 mg/m^2;   Drug: Etarfolatide;   Drug: Folic acid;   Drug: Premedication for Paclitaxel
Outcome Measures: Progression Free Survival (PFS);   Objective Response Rate (Complete Response [CR] + Partial Response [PR]);   Clinical Benefit Rate (CR + PR + Stable Disease [SD] for >=6 months);   Overall Survival (OS)
13 Recruiting MAGIC vs. CROSS Upper GI. ICORG 10-14, V3
Conditions: Adenocarcinoma of the Oesophagus;   Adenocarcinoma of the Oesophago-gastric Junction;   Oesophageal Tumours;   Junctional Tumours;   Oesophageal Cancer
Interventions: Drug: Epirubicin;   Drug: Cisplatin;   Drug: 5 Flourouracil/ Capecitabine;   Radiation: (41.4 Gy/23 fractions);   Drug: Paclitaxel;   Drug: Carboplatin
Outcome Measure: Overall survival
14 Recruiting Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Condition: Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Copanlisib (BAY80-6946)
Outcome Measures: Adverse event collection;   Maximum tolerated dose, measured by adverse event profile;   Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed);   Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only);   Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15;   Number of patients with mutational status;   Tumor Response as measured by RECIST 1.1 criteria
15 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
Outcome Measures: Antitumor activity, as measured by tumor response rate of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer;   Time to progression;   Survival;   Overall survival;   Toxicity of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer
16 Unknown  Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
Conditions: Brain and Central Nervous System Tumors;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Biological: filgrastim;   Biological: lenograstim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: paclitaxel
Outcome Measures: Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I);   Response rates (phase I);   Failure-free survival (phase I);   Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I);   Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)